Literature DB >> 15340043

Mechanisms of agonist action at D2 dopamine receptors.

David J Roberts1, Hong Lin, Philip G Strange.   

Abstract

In this study, we investigated the biochemical mechanisms of agonist action at the G protein-coupled D2 dopamine receptor expressed in Chinese hamster ovary cells. Stimulation of guanosine 5'-O-(3-[35S]thio)triphosphate ([35S]GTPgammaS) binding by full and partial agonists was determined at different concentrations of [35S]GTPgammaS (0.1 and 10 nM) and in the presence of different concentrations of GDP. At both concentrations of [35S]GTPgammaS, increasing GDP decreased the [35S]GTPgammaS binding observed with maximally stimulating concentrations of agonist, with partial agonists exhibiting greater sensitivity to the effects of GDP than full agonists. The relative efficacy of partial agonists was greater at the lower GDP concentrations. Concentration-response experiments were performed for a range of agonists at the two [35S]GTPgammaS concentrations and with different concentrations of GDP. At 0.1 nM [35S]GTPgammaS, the potency of both full and partial agonists was dependent on the GDP concentration in the assays. At 10 nM [35S]GTPgammaS, the potency of full agonists exhibited a greater dependence on the GDP concentration, whereas the potency of partial agonists was virtually independent of GDP. We concluded that at the lower [35S]GTPgammaS concentration, the rate-determining step in G protein activation is the binding of [35S]GTPgammaS to the G protein. At the higher [35S]GTPgammaS concentration, for full agonists, [35S]GTPgammaS binding remains the slowest step, whereas for partial agonists, another (GDP-independent) step, probably ternary complex breakdown, becomes rate-determining.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15340043     DOI: 10.1124/mol.104.004077

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  9 in total

Review 1.  Use of the GTPγS ([35S]GTPγS and Eu-GTPγS) binding assay for analysis of ligand potency and efficacy at G protein-coupled receptors.

Authors:  Philip G Strange
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

Review 2.  Agonist binding, agonist affinity and agonist efficacy at G protein-coupled receptors.

Authors:  P G Strange
Journal:  Br J Pharmacol       Date:  2008-01-28       Impact factor: 8.739

Review 3.  Structure and dynamics of GPCR signaling complexes.

Authors:  Daniel Hilger; Matthieu Masureel; Brian K Kobilka
Journal:  Nat Struct Mol Biol       Date:  2018-01-08       Impact factor: 15.369

4.  A2A Adenosine Receptor Partial Agonism Related to Structural Rearrangements in an Activation Microswitch.

Authors:  Matthew T Eddy; Bryan T Martin; Kurt Wüthrich
Journal:  Structure       Date:  2020-11-24       Impact factor: 5.006

5.  Assays for enhanced activity of low efficacy partial agonists at the D(2) dopamine receptor.

Authors:  H Lin; S G N Saisch; P G Strange
Journal:  Br J Pharmacol       Date:  2006-08-21       Impact factor: 8.739

Review 6.  Clozapine, atypical antipsychotics, and the benefits of fast-off D2 dopamine receptor antagonism.

Authors:  Georges Vauquelin; Sophie Bostoen; Patrick Vanderheyden; Philip Seeman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-02-14       Impact factor: 3.000

7.  Positron emission tomography imaging of D(2/3) agonist binding in healthy human subjects with the radiotracer [(11)C]-N-propyl-norapomorphine: preliminary evaluation and reproducibility studies.

Authors:  Rajesh Narendran; W Gordon Frankle; N Scott Mason; Charles M Laymon; Brian J Lopresti; Julie C Price; Steve Kendro; Shivangi Vora; Maralee Litschge; James M Mountz; Chester A Mathis
Journal:  Synapse       Date:  2009-07       Impact factor: 2.562

8.  Dopamine receptor repertoire of human granulosa cells.

Authors:  Veronica Rey-Ares; Nikolai Lazarov; Dieter Berg; Ulrike Berg; Lars Kunz; Artur Mayerhofer
Journal:  Reprod Biol Endocrinol       Date:  2007-10-25       Impact factor: 5.211

9.  Quantification of kappa opioid receptor ligand potency, efficacy and desensitization using a real-time membrane potential assay.

Authors:  Yuanzi Zhao; Anand A Joshi; Jane V Aldrich; Thomas F Murray
Journal:  Biomed Pharmacother       Date:  2021-09-15       Impact factor: 6.529

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.